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A B S T R A C T
Lennox–Gastaut syndrome (LGS) is a well-deﬁned epileptic encephalopathy highly drug resistant. The
ﬁrst-line treatment option is valproate (VPA), usually in combination with lamotrigine. VPA has been
linked to serious hepatotoxicity. We report a 22-year-old liver transplanted patient with LGS
successfully treated with VPA in combination with phenobarbital (100 mg/d; blood level: 36 mg/l),
lamotrigine (125 mg/d; blood level: 4.81 mg/l) and topiramtate (175 mg/d), as well as immunosup-
pressive, antiviral, anti-anemic, hypo-phosphoric and alkaline medication. On VPA 1000 mg/d, the
seizure frequency decreased signiﬁcantly. Taking into consideration the patient’s good tolerance and the
normal liver function, VPA was increased to 1500 mg/d. At this dose the daily drop attacks and
generalized tonic–clonic seizures totally ceased. The patient presented only some tonic seizures around
awakening. During many years, VPA was avoided in this patient because of its potential hepatotoxicity.
However the good functioning of the transplanted liver permitted its introduction. VPA can be used
safely in liver transplanted patients under the strict control of the hepatic function.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.1. Introduction
Lennox–Gastaut syndrome (LGS) is a well-deﬁned epileptic
encephalopathy highly drug resistant. The ﬁrst-line treatment
option is valproate (VPA), usually in combination with lamo-
trigine.1,2 VPA has been linked to serious hepatotoxicity. It is rare,
typically idiosyncratic but it is recommended to avoid its
utilization in patient with pre-existing liver disease, in patients
with personal or family history of metabolic diseases implying
beta-oxydation, mithocondrial and peroxisomal functions.3,4
Careful monitoring should be provided when VPA is prescribed
in children under the age of 2 years, in association with enzyme-
inducing drugs, neurometabolic diseases or hereditary metabolic
disorders.3,4 In these situations, administration of VPA should
be done after careful evaluation of the risk/beneﬁt ratio. We
present a liver transplanted patient with LGS successfully treated
with VPA.§ Dr Crespel, Genton, Gelisse have received support from pharmaceutical
companies (Sanoﬁ-Aventis, UCB and Eisai) for teaching programs.
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doi:10.1016/j.seizure.2011.02.0052. Case report
The history of this patient begins at the age of 2 months when
she presented severe hepatic failure. The diagnostic of congenital
biliary atresia was made and she was immediately submitted to a
hepatoportoenterostomy. This failed and one year later she had a
ﬁrst liver transplant. Unfortunately, it was rejected and the child
fell in hepatic coma. In November 1989, at age 2 years, she received
her second transplant and was put on immunosuppressive
medications. She rapidly developed chronic renal insufﬁciency,
arterial hypertension. Epilepsy appeared in September 1990, at the
age of 3 years, with two episodes of absence status. Her ﬁrst EEGs
were normal and she was treated with intermittent benzodiaze-
pines. Generalized tonic–clonic seizures (GTCS), tonic seizures, and
atypical absences appeared with increasing frequency. She could
present multiple traumatic drop attacks per day, often causing
surgical intervention. Her behavior became hyperactive and her
learning abilities declined signiﬁcantly. The EEGs showed diffuse
slow spikes with polyspikes-waves and fast rhythms during sleep.
MRI demonstrated a diffuse nonspeciﬁc cerebral atrophy. Clonaz-
epam, clobazam, lamotrigine, levetiracetam, phenobarbital, etho-
suximide, topiramate, ACTH (tetracosactide) and hydrocortisone
were successively tried (Table 1), always under strict control of
renal and hepatic functions. The epilepsy nevertheless remained
intractable.vier Ltd. All rights reserved.
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Fig. 1. EEG (International 10–20 electrode placement system with supplementary anterior/inferior temporal electrodes (TA1, T1, TA2, T2), EMG (Right and Left deltoid),
respiration (Pneumo). Left segment at 10 mm/s and 100 mV/cm. Recording during nREM sleep and a subtle tonic seizure occurs. Seizure onset is at the 5th second, with
disappearance of the interictal changes (diffuses slow spike-waves) giving a false impression of normalization. At the beginning of the seizure, there is fast activity clearly seen
on the right posterior regions. During this seizure, there is no contraction of the deltoidmuscles but there is a prolonged apnea (15 s). Right segment, grey area at 30 mm/s and
70mV/cm.
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showed slow background activity fragmented by multiple general-
ized slow spike-waves and polyspike-waves, andmany subtle tonic
seizures (Fig. 1), as well as enhanced epileptic abnormality and
prolonged discharges of fast activity during sleep. A diagnosis of LGS
was proposed and after a comprehensive discussion with the
patient’s nephrologists and hepato-gastro-enterologist, VPA was
started. It was titrated very carefully with 100 mg weekly
increments up to 1000 mg/d (blood level 55.6 mg/l). The baseline
therapy included phenobarbital (100 mg/d; blood level: 36 mg/l),
lamotrigine (125mg/d; blood level: 4.81 mg/l) and topiramate
(175mg/d), as well as immunosuppressive, antiviral, anti-anemic,
hypo-phosphoric and alkaline medication. The ﬁrst four months,
hepatic and renal functions were controlled every week, after that
everymonth. The values of transaminaseswere in reference ranges:
aspartate transaminasebetween18and44 U/l (<46 U/l) andalanine
transaminase between 16 and 50 (<52 U/l). On VPA 1000mg/d, theTable 1
Treatment history.
Age (years) Antiepileptic drugs
3–8y CNZ: 1–2mg/d
9y CNZ: 3mg/d
11y CLB: 30mg/d
16y LTG: 100mg/d; CLB 30mg/d
17y LTG: 150mg/d; CLB 35mg/d
18y LEV: 1000mg/d; LTG: 200mg/d; CLB 40mg/d;
19y PB: 100mg/d; LTG: 250mg/d; CLB: 40mg/d
20y ESM: 750mg/d; PB: 100mg/d; LTG: 250mg/d; CLB: 40mg/d
(ACTH) Tetracosactide: 0.5mg/m2 during 8 days
Hydrocortisone: 100mg per 48h during 3 months
21y TPM: 100/d; PB: 100mg/d; LTG: 250mg/d
22y TPM: 150/d; PB: 100mg/d; LTG: 250mg/d
22.5 y VPA: 1000mg/d; TPM: 175/d; PB: 100mg/d; LTG: 125mg/d
23y VPA: 1500mg/d; TPM: 175/d; PB: 50mg/d; LTG: 125mg/d
CNZ: clonazepam; CLB: clobazam; LTG: lamotrigine; LEV: levetiracetam; PB:
phenobarbital; ESM: ethosuximide; TPM: topiramate; VPA: valproate.seizure frequency decreased signiﬁcantly. Taking into consideration
good tolerability and normal liver function, we decreased pheno-
barbital to50 mg/dandincreasedVPAto1500mg/d (Table1).At this
dose the daily drop attacks and GTCS totally ceased, with only some
tonic seizures persisting around awakening.
3. Discussion
Aminor increase in serum aminotransferases is observed in 30–
50% of patients treated with VPA. It appears to be dose related,
transient and is observedmore commonlyduring initial therapyand
in patients comedicated with phenobarbital or phenytoin.5 When
this increase remains moderate, lower than two to three times
baseline values, asymptomatic, and without any abnormal changes
in other liver function test results, the treatment may be continued.
VPA is a treatment of choice in LGS especially in association with
lamotrigine. During many years, VPA was avoided in this patient
because of its potential hepatotoxicity. However the good function-
ing of the transplanted liver permitted its introduction. This patient
had signiﬁcant seizure reduction,without falls, andherqualityof life
was dramatically improved. VPA was used safely in a liver
transplanted patient under the strict control of the hepatic function.
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